On January 20, 2026, Lisata Therapeutics, Inc. entered a term sheet with Kuva Labs Inc. for a proposed acquisition, where Kuva plans to tender an offer of $4.00 per share for all outstanding shares of Lisata's common stock. Additionally, accepted shares would receive contingent value rights totaling up to $2.00, linked to future developments of Certepetide.